Trial Outcomes & Findings for Treatment of Symptoms After Stent Placement for Urinary Tract Obstruction (NCT NCT01741454)
NCT ID: NCT01741454
Last Updated: 2019-07-10
Results Overview
The ureteral stent symptom questionnaire contains 36 items from the 5 subscales: urinary index (11-items, total range of scores 11-54, The range of the mean score is 1-4.9), pain (8-items, total range of scores 5-27. Two items are not included in the calculation. The range of the mean score is 0.83-4.5), general health (6-items, total range of scores 4-28. The range of the mean score is 0.67-4.67), work (if stent influence patients work; 7-items, total range of scores 3-15. Four items are not included in the calculation. The range of the mean score is 1-5), and sexual matters (4-items, total range of scores 2-10. Two items are not included in the calculation. The range of the mean score is 1-5). In all cases, higher scores indicate worse outcomes. The score for each subscale is summed and divided by the number of items on the subscale. The group mean for each subscale is reported, the score is not normalized.
COMPLETED
PHASE4
181 participants
Up to 24 hours prior to stent insertion
2019-07-10
Participant Flow
The enrollment is slow, drop out rate is high, thus, we decide to stop enrolling.
Participant milestones
| Measure |
Tamsulosin Plus Placebo 7 Day
Tamsulosin is a selective α1a-blocker (FlomaxTM), generic since 2009. It is an antagonist of α1-mediated contraction of prostate, bladder and proximal urethral smooth muscle, and as such, reduces urethral pressure and resistance, bladder outlet resistance, bladder hyperactivity, and consequently lower urinary tract symptoms.
Tamsulosin: 0.4 mg by mouth once per day for 7 days
|
Tamsulosin Plus Tolterodine ER 7 Day
Tamsulosin is a selective α1a-blocker (FlomaxTM), generic since 2009. It is an antagonist of α1-mediated contraction of prostate, bladder and proximal urethral smooth muscle, and as such, reduces urethral pressure and resistance, bladder outlet resistance, bladder hyperactivity, and consequently lower urinary tract symptoms.
Tolterodine ER is an anticholinergic agent, which is used as one of the first line agents for detrusor overactivity.
Tamsulosin: 0.4 mg by mouth once per day for 7 days
Tolterodine ER: 4 mg by mouth once a day for 7 days
|
Tamsulosin Plus Placebo 21 Day
Tamsulosin is a selective α1a-blocker (FlomaxTM), generic since 2009. It is an antagonist of α1-mediated contraction of prostate, bladder and proximal urethral smooth muscle, and as such, reduces urethral pressure and resistance, bladder outlet resistance, bladder hyperactivity, and consequently lower urinary tract symptoms.
Tamsulosin: 0.4 mg by mouth once per day for 21 days
|
Tamsulosin Plus Tolterodine ER 21 Day
Tamsulosin is a selective α1a-blocker (FlomaxTM), generic since 2009. It is an antagonist of α1-mediated contraction of prostate, bladder and proximal urethral smooth muscle, and as such, reduces urethral pressure and resistance, bladder outlet resistance, bladder hyperactivity, and consequently lower urinary tract symptoms.
Tolterodine ER is an anticholinergic agent, which is used as one of the first line agents for detrusor overactivity.
Tamsulosin: 0.4 mg by mouth once per day for 21 days
Tolterodine ER: 4 mg by mouth once a day for 21 days
|
|---|---|---|---|---|
|
Overall Study
STARTED
|
49
|
50
|
39
|
43
|
|
Overall Study
COMPLETED
|
36
|
44
|
22
|
21
|
|
Overall Study
NOT COMPLETED
|
13
|
6
|
17
|
22
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Race and Ethnicity were not collected from any participant.
Baseline characteristics by cohort
| Measure |
Tamsulosin Plus Placebo 7 Day Treatment
n=36 Participants
Tamsulosin is a selective α1a-blocker (FlomaxTM), generic since 2009. It is an antagonist of α1-mediated contraction of prostate, bladder and proximal urethral smooth muscle, and as such, reduces urethral pressure and resistance, bladder outlet resistance, bladder hyperactivity, and consequently lower urinary tract symptoms.
Tamsulosin: 0.4 mg by mouth once per day.
|
Tamsulosin Plus Tolterodine ER 7 Day Treatment
n=44 Participants
Tamsulosin is a selective α1a-blocker (FlomaxTM), generic since 2009. It is an antagonist of α1-mediated contraction of prostate, bladder and proximal urethral smooth muscle, and as such, reduces urethral pressure and resistance, bladder outlet resistance, bladder hyperactivity, and consequently lower urinary tract symptoms.
Tolterodine ER is an anticholinergic agent, which is used as one of the first line agents for detrusor overactivity.
Tamsulosin: 0.4 mg by mouth once per day.
Tolterodine ER: 4 mg by mouth once a day.
|
Tamsulosin Plus Placebo 21 Day Treatment
n=22 Participants
Tamsulosin is a selective α1a-blocker (FlomaxTM), generic since 2009. It is an antagonist of α1-mediated contraction of prostate, bladder and proximal urethral smooth muscle, and as such, reduces urethral pressure and resistance, bladder outlet resistance, bladder hyperactivity, and consequently lower urinary tract symptoms.
Tamsulosin: 0.4 mg by mouth once per day.
|
Tamsulosin Plus Tolterodine ER 21 Day Treatment
n=21 Participants
Tamsulosin is a selective α1a-blocker (FlomaxTM), generic since 2009. It is an antagonist of α1-mediated contraction of prostate, bladder and proximal urethral smooth muscle, and as such, reduces urethral pressure and resistance, bladder outlet resistance, bladder hyperactivity, and consequently lower urinary tract symptoms.
Tolterodine ER is an anticholinergic agent, which is used as one of the first line agents for detrusor overactivity.
Tamsulosin: 0.4 mg by mouth once per day.
Tolterodine ER: 4 mg by mouth once a day.
|
Total
n=123 Participants
Total of all reporting groups
|
|---|---|---|---|---|---|
|
Age, Continuous
|
48.8 years
STANDARD_DEVIATION 18 • n=36 Participants
|
51.5 years
STANDARD_DEVIATION 12.7 • n=44 Participants
|
57.3 years
STANDARD_DEVIATION 10.3 • n=22 Participants
|
56.9 years
STANDARD_DEVIATION 16.2 • n=21 Participants
|
53.4 years
STANDARD_DEVIATION 14.8 • n=123 Participants
|
|
Sex: Female, Male
Female
|
15 Participants
n=36 Participants
|
25 Participants
n=44 Participants
|
10 Participants
n=22 Participants
|
11 Participants
n=21 Participants
|
61 Participants
n=123 Participants
|
|
Sex: Female, Male
Male
|
21 Participants
n=36 Participants
|
19 Participants
n=44 Participants
|
12 Participants
n=22 Participants
|
10 Participants
n=21 Participants
|
62 Participants
n=123 Participants
|
|
Race and Ethnicity Not Collected
|
—
|
—
|
—
|
—
|
0 Participants
Race and Ethnicity were not collected from any participant.
|
|
Region of Enrollment
United States
|
36 Participants
n=36 Participants
|
44 Participants
n=44 Participants
|
22 Participants
n=22 Participants
|
21 Participants
n=21 Participants
|
123 Participants
n=123 Participants
|
PRIMARY outcome
Timeframe: Up to 24 hours prior to stent insertionPopulation: For all sub-scales, we reported the average score, the higher values suggest worse outcomes.
The ureteral stent symptom questionnaire contains 36 items from the 5 subscales: urinary index (11-items, total range of scores 11-54, The range of the mean score is 1-4.9), pain (8-items, total range of scores 5-27. Two items are not included in the calculation. The range of the mean score is 0.83-4.5), general health (6-items, total range of scores 4-28. The range of the mean score is 0.67-4.67), work (if stent influence patients work; 7-items, total range of scores 3-15. Four items are not included in the calculation. The range of the mean score is 1-5), and sexual matters (4-items, total range of scores 2-10. Two items are not included in the calculation. The range of the mean score is 1-5). In all cases, higher scores indicate worse outcomes. The score for each subscale is summed and divided by the number of items on the subscale. The group mean for each subscale is reported, the score is not normalized.
Outcome measures
| Measure |
Tamsulosin Plus Placebo 7-day Treatment
n=36 Participants
Tamsulosin is a selective α1a-blocker (FlomaxTM), generic since 2009. It is an antagonist of α1-mediated contraction of prostate, bladder and proximal urethral smooth muscle, and as such, reduces urethral pressure and resistance, bladder outlet resistance, bladder hyperactivity, and consequently lower urinary tract symptoms.
Tamsulosin: 0.4 mg by mouth once per day for 7 dyas
|
Tamsulosin Plus Tolterodine ER 7-day Treatment
n=44 Participants
Tamsulosin is a selective α1a-blocker (FlomaxTM), generic since 2009. It is an antagonist of α1-mediated contraction of prostate, bladder and proximal urethral smooth muscle, and as such, reduces urethral pressure and resistance, bladder outlet resistance, bladder hyperactivity, and consequently lower urinary tract symptoms.
Tolterodine ER is an anticholinergic agent, which is used as one of the first line agents for detrusor overactivity.
Tamsulosin: 0.4 mg by mouth once per day for 7 days
Tolterodine ER: 4 mg by mouth once a day for 7 days
|
Tamsulosin Plus Placebo 21-day Treatment
n=22 Participants
Tamsulosin is a selective α1a-blocker (FlomaxTM), generic since 2009. It is an antagonist of α1-mediated contraction of prostate, bladder and proximal urethral smooth muscle, and as such, reduces urethral pressure and resistance, bladder outlet resistance, bladder hyperactivity, and consequently lower urinary tract symptoms.
Tamsulosin: 0.4 mg by mouth once per day for 21 dyas
|
Tamsulosin Plus Tolterodine ER 21-day Treatment
n=21 Participants
Tamsulosin is a selective α1a-blocker (FlomaxTM), generic since 2009. It is an antagonist of α1-mediated contraction of prostate, bladder and proximal urethral smooth muscle, and as such, reduces urethral pressure and resistance, bladder outlet resistance, bladder hyperactivity, and consequently lower urinary tract symptoms.
Tolterodine ER is an anticholinergic agent, which is used as one of the first line agents for detrusor overactivity.
Tamsulosin: 0.4 mg by mouth once per day for 21days
Tolterodine ER: 4 mg by mouth once a day for 21 days
|
|---|---|---|---|---|
|
Ureteral Stent Symptom Questionnaire Score Up to 24 Hours Prior to Stent Insertion
Work
|
1.65 score on a scale
Standard Deviation 0.83
|
1.76 score on a scale
Standard Deviation 0.91
|
2.05 score on a scale
Standard Deviation 0.96
|
1.18 score on a scale
Standard Deviation 0.4
|
|
Ureteral Stent Symptom Questionnaire Score Up to 24 Hours Prior to Stent Insertion
Sexual matters
|
1.60 score on a scale
Standard Deviation 0.6
|
1.41 score on a scale
Standard Deviation 0.41
|
1.77 score on a scale
Standard Deviation 0.73
|
1.57 score on a scale
Standard Deviation 0.63
|
|
Ureteral Stent Symptom Questionnaire Score Up to 24 Hours Prior to Stent Insertion
Pain score
|
1.95 score on a scale
Standard Deviation 0.74
|
2.13 score on a scale
Standard Deviation 0.94
|
2.49 score on a scale
Standard Deviation 0.7
|
1.88 score on a scale
Standard Deviation 0.7
|
|
Ureteral Stent Symptom Questionnaire Score Up to 24 Hours Prior to Stent Insertion
Urinary index
|
1.76 score on a scale
Standard Deviation 0.46
|
1.84 score on a scale
Standard Deviation 0.39
|
2.02 score on a scale
Standard Deviation 0.27
|
1.93 score on a scale
Standard Deviation 0.48
|
|
Ureteral Stent Symptom Questionnaire Score Up to 24 Hours Prior to Stent Insertion
General health score
|
1.87 score on a scale
Standard Deviation 0.55
|
2.04 score on a scale
Standard Deviation 0.83
|
2.15 score on a scale
Standard Deviation 0.6
|
2.07 score on a scale
Standard Deviation 0.6
|
PRIMARY outcome
Timeframe: 42-48 hours post-stent insertionPopulation: Same
The ureteral stent symptom questionnaire contains 36 items from the 5 subscales: urinary index (11-items, total range of scores 11-54, The range of the mean score is 1-4.9), pain (8-items, total range of scores 5-27. Two items are not included in the calculation. The range of the mean score is 0.83-4.5), general health (6-items, total range of scores 4-28. The range of the mean score is 0.67-4.67), work (if stent influence patients work; 7-items, total range of scores 3-15. Four items are not included in the calculation. The range of the mean score is 1-5), and sexual matters (4-items, total range of scores 2-10. Two items are not included in the calculation. The range of the mean score is 1-5). In all cases, higher scores indicate worse outcomes. The score for each subscale is summed and divided by the number of items on the subscale. The group mean for each subscale is reported, the score is not normalized.
Outcome measures
| Measure |
Tamsulosin Plus Placebo 7-day Treatment
n=36 Participants
Tamsulosin is a selective α1a-blocker (FlomaxTM), generic since 2009. It is an antagonist of α1-mediated contraction of prostate, bladder and proximal urethral smooth muscle, and as such, reduces urethral pressure and resistance, bladder outlet resistance, bladder hyperactivity, and consequently lower urinary tract symptoms.
Tamsulosin: 0.4 mg by mouth once per day for 7 dyas
|
Tamsulosin Plus Tolterodine ER 7-day Treatment
n=44 Participants
Tamsulosin is a selective α1a-blocker (FlomaxTM), generic since 2009. It is an antagonist of α1-mediated contraction of prostate, bladder and proximal urethral smooth muscle, and as such, reduces urethral pressure and resistance, bladder outlet resistance, bladder hyperactivity, and consequently lower urinary tract symptoms.
Tolterodine ER is an anticholinergic agent, which is used as one of the first line agents for detrusor overactivity.
Tamsulosin: 0.4 mg by mouth once per day for 7 days
Tolterodine ER: 4 mg by mouth once a day for 7 days
|
Tamsulosin Plus Placebo 21-day Treatment
n=22 Participants
Tamsulosin is a selective α1a-blocker (FlomaxTM), generic since 2009. It is an antagonist of α1-mediated contraction of prostate, bladder and proximal urethral smooth muscle, and as such, reduces urethral pressure and resistance, bladder outlet resistance, bladder hyperactivity, and consequently lower urinary tract symptoms.
Tamsulosin: 0.4 mg by mouth once per day for 21 dyas
|
Tamsulosin Plus Tolterodine ER 21-day Treatment
n=21 Participants
Tamsulosin is a selective α1a-blocker (FlomaxTM), generic since 2009. It is an antagonist of α1-mediated contraction of prostate, bladder and proximal urethral smooth muscle, and as such, reduces urethral pressure and resistance, bladder outlet resistance, bladder hyperactivity, and consequently lower urinary tract symptoms.
Tolterodine ER is an anticholinergic agent, which is used as one of the first line agents for detrusor overactivity.
Tamsulosin: 0.4 mg by mouth once per day for 21days
Tolterodine ER: 4 mg by mouth once a day for 21 days
|
|---|---|---|---|---|
|
Ureteral Stent Symptom Questionnaire Score
Pain score
|
2.66 score on a scale
Standard Deviation 0.79
|
2.89 score on a scale
Standard Deviation 0.98
|
2.9 score on a scale
Standard Deviation 0.95
|
2.71 score on a scale
Standard Deviation 0.76
|
|
Ureteral Stent Symptom Questionnaire Score
Work
|
2.04 score on a scale
Standard Deviation 0.97
|
2.92 score on a scale
Standard Deviation 1.29
|
2.1 score on a scale
Standard Deviation 1.05
|
1.79 score on a scale
Standard Deviation 1.21
|
|
Ureteral Stent Symptom Questionnaire Score
Urinary index
|
2.95 score on a scale
Standard Deviation 0.45
|
2.91 score on a scale
Standard Deviation 0.55
|
2.98 score on a scale
Standard Deviation 0.64
|
2.83 score on a scale
Standard Deviation 0.63
|
|
Ureteral Stent Symptom Questionnaire Score
General health score
|
2.35 score on a scale
Standard Deviation 0.74
|
2.69 score on a scale
Standard Deviation 0.85
|
2.64 score on a scale
Standard Deviation 0.85
|
2.78 score on a scale
Standard Deviation 0.95
|
|
Ureteral Stent Symptom Questionnaire Score
Sexual matters
|
2.07 score on a scale
Standard Deviation 1.01
|
2 score on a scale
Standard Deviation 0.91
|
1.83 score on a scale
Standard Deviation 0.76
|
1.75 score on a scale
Standard Deviation 1.06
|
PRIMARY outcome
Timeframe: 5-7 days post-stent insertionPopulation: same
The ureteral stent symptom questionnaire contains 36 items from the 5 subscales: urinary index (11-items, total range of scores 11-54, The range of the mean score is 1-4.9), pain (8-items, total range of scores 5-27. Two items are not included in the calculation. The range of the mean score is 0.83-4.5), general health (6-items, total range of scores 4-28. The range of the mean score is 0.67-4.67), work (if stent influence patients work; 7-items, total range of scores 3-15. Four items are not included in the calculation. The range of the mean score is 1-5), and sexual matters (4-items, total range of scores 2-10. Two items are not included in the calculation. The range of the mean score is 1-5). In all cases, higher scores indicate worse outcomes. The score for each subscale is summed and divided by the number of items on the subscale. The group mean for each subscale is reported, the score is not normalized.
Outcome measures
| Measure |
Tamsulosin Plus Placebo 7-day Treatment
n=36 Participants
Tamsulosin is a selective α1a-blocker (FlomaxTM), generic since 2009. It is an antagonist of α1-mediated contraction of prostate, bladder and proximal urethral smooth muscle, and as such, reduces urethral pressure and resistance, bladder outlet resistance, bladder hyperactivity, and consequently lower urinary tract symptoms.
Tamsulosin: 0.4 mg by mouth once per day for 7 dyas
|
Tamsulosin Plus Tolterodine ER 7-day Treatment
n=44 Participants
Tamsulosin is a selective α1a-blocker (FlomaxTM), generic since 2009. It is an antagonist of α1-mediated contraction of prostate, bladder and proximal urethral smooth muscle, and as such, reduces urethral pressure and resistance, bladder outlet resistance, bladder hyperactivity, and consequently lower urinary tract symptoms.
Tolterodine ER is an anticholinergic agent, which is used as one of the first line agents for detrusor overactivity.
Tamsulosin: 0.4 mg by mouth once per day for 7 days
Tolterodine ER: 4 mg by mouth once a day for 7 days
|
Tamsulosin Plus Placebo 21-day Treatment
n=22 Participants
Tamsulosin is a selective α1a-blocker (FlomaxTM), generic since 2009. It is an antagonist of α1-mediated contraction of prostate, bladder and proximal urethral smooth muscle, and as such, reduces urethral pressure and resistance, bladder outlet resistance, bladder hyperactivity, and consequently lower urinary tract symptoms.
Tamsulosin: 0.4 mg by mouth once per day for 21 dyas
|
Tamsulosin Plus Tolterodine ER 21-day Treatment
n=21 Participants
Tamsulosin is a selective α1a-blocker (FlomaxTM), generic since 2009. It is an antagonist of α1-mediated contraction of prostate, bladder and proximal urethral smooth muscle, and as such, reduces urethral pressure and resistance, bladder outlet resistance, bladder hyperactivity, and consequently lower urinary tract symptoms.
Tolterodine ER is an anticholinergic agent, which is used as one of the first line agents for detrusor overactivity.
Tamsulosin: 0.4 mg by mouth once per day for 21days
Tolterodine ER: 4 mg by mouth once a day for 21 days
|
|---|---|---|---|---|
|
Ureteral Stent Symptom Questionnaire Score 5-7 Days Post-stent Insertion
General health score
|
2.34 score on a scale
Standard Deviation 0.92
|
2.33 score on a scale
Standard Deviation 0.8
|
2.52 score on a scale
Standard Deviation 0.83
|
2.28 score on a scale
Standard Deviation 0.75
|
|
Ureteral Stent Symptom Questionnaire Score 5-7 Days Post-stent Insertion
Urinary index
|
2.46 score on a scale
Standard Deviation 0.58
|
2.55 score on a scale
Standard Deviation 0.63
|
2.49 score on a scale
Standard Deviation 0.48
|
2.46 score on a scale
Standard Deviation 0.66
|
|
Ureteral Stent Symptom Questionnaire Score 5-7 Days Post-stent Insertion
Work
|
2.81 score on a scale
Standard Deviation 0.88
|
2.61 score on a scale
Standard Deviation 1.19
|
1.94 score on a scale
Standard Deviation 1.05
|
1.47 score on a scale
Standard Deviation 0.67
|
|
Ureteral Stent Symptom Questionnaire Score 5-7 Days Post-stent Insertion
Sexual matters
|
1.5 score on a scale
Standard Deviation 0.4
|
1.59 score on a scale
Standard Deviation 0.76
|
1.75 score on a scale
Standard Deviation 0.69
|
2.9 score on a scale
Standard Deviation 1.19
|
|
Ureteral Stent Symptom Questionnaire Score 5-7 Days Post-stent Insertion
Pain score
|
2.39 score on a scale
Standard Deviation 0.94
|
2.49 score on a scale
Standard Deviation 0.97
|
2.58 score on a scale
Standard Deviation 0.83
|
2.4 score on a scale
Standard Deviation 0.86
|
PRIMARY outcome
Timeframe: Up to 24 hours after stent removal. Removal will occur 5 to 7 days after insertion.Population: same
The ureteral stent symptom questionnaire contains 36 items from the 5 subscales: urinary index (11-items, total range of scores 11-54, The range of the mean score is 1-4.9), pain (8-items, total range of scores 5-27. Two items are not included in the calculation. The range of the mean score is 0.83-4.5), general health (6-items, total range of scores 4-28. The range of the mean score is 0.67-4.67), work (if stent influence patients work; 7-items, total range of scores 3-15. Four items are not included in the calculation. The range of the mean score is 1-5), and sexual matters (4-items, total range of scores 2-10. Two items are not included in the calculation. The range of the mean score is 1-5). In all cases, higher scores indicate worse outcomes. The score for each subscale is summed and divided by the number of items on the subscale. The group mean for each subscale is reported, the score is not normalized.
Outcome measures
| Measure |
Tamsulosin Plus Placebo 7-day Treatment
n=36 Participants
Tamsulosin is a selective α1a-blocker (FlomaxTM), generic since 2009. It is an antagonist of α1-mediated contraction of prostate, bladder and proximal urethral smooth muscle, and as such, reduces urethral pressure and resistance, bladder outlet resistance, bladder hyperactivity, and consequently lower urinary tract symptoms.
Tamsulosin: 0.4 mg by mouth once per day for 7 dyas
|
Tamsulosin Plus Tolterodine ER 7-day Treatment
n=44 Participants
Tamsulosin is a selective α1a-blocker (FlomaxTM), generic since 2009. It is an antagonist of α1-mediated contraction of prostate, bladder and proximal urethral smooth muscle, and as such, reduces urethral pressure and resistance, bladder outlet resistance, bladder hyperactivity, and consequently lower urinary tract symptoms.
Tolterodine ER is an anticholinergic agent, which is used as one of the first line agents for detrusor overactivity.
Tamsulosin: 0.4 mg by mouth once per day for 7 days
Tolterodine ER: 4 mg by mouth once a day for 7 days
|
Tamsulosin Plus Placebo 21-day Treatment
n=22 Participants
Tamsulosin is a selective α1a-blocker (FlomaxTM), generic since 2009. It is an antagonist of α1-mediated contraction of prostate, bladder and proximal urethral smooth muscle, and as such, reduces urethral pressure and resistance, bladder outlet resistance, bladder hyperactivity, and consequently lower urinary tract symptoms.
Tamsulosin: 0.4 mg by mouth once per day for 21 dyas
|
Tamsulosin Plus Tolterodine ER 21-day Treatment
n=21 Participants
Tamsulosin is a selective α1a-blocker (FlomaxTM), generic since 2009. It is an antagonist of α1-mediated contraction of prostate, bladder and proximal urethral smooth muscle, and as such, reduces urethral pressure and resistance, bladder outlet resistance, bladder hyperactivity, and consequently lower urinary tract symptoms.
Tolterodine ER is an anticholinergic agent, which is used as one of the first line agents for detrusor overactivity.
Tamsulosin: 0.4 mg by mouth once per day for 21days
Tolterodine ER: 4 mg by mouth once a day for 21 days
|
|---|---|---|---|---|
|
Ureteral Stent Symptom Questionnaire Score Up to 24 Hours After Stent Removal
Pain score
|
1.66 score on a scale
Standard Deviation 0.91
|
1.66 score on a scale
Standard Deviation 0.79
|
1.97 score on a scale
Standard Deviation 1.01
|
2.08 score on a scale
Standard Deviation 0.47
|
|
Ureteral Stent Symptom Questionnaire Score Up to 24 Hours After Stent Removal
Sexual matters
|
1.42 score on a scale
Standard Deviation 0.4
|
1.3 score on a scale
Standard Deviation 0.35
|
1.58 score on a scale
Standard Deviation 0.58
|
2.42 score on a scale
Standard Deviation 1.5
|
|
Ureteral Stent Symptom Questionnaire Score Up to 24 Hours After Stent Removal
Urinary index
|
1.72 score on a scale
Standard Deviation 0.45
|
1.91 score on a scale
Standard Deviation 0.53
|
1.85 score on a scale
Standard Deviation 0.46
|
2.14 score on a scale
Standard Deviation 0.61
|
|
Ureteral Stent Symptom Questionnaire Score Up to 24 Hours After Stent Removal
General health score
|
1.73 score on a scale
Standard Deviation 0.71
|
1.67 score on a scale
Standard Deviation 0.62
|
1.84 score on a scale
Standard Deviation 1.02
|
1.99 score on a scale
Standard Deviation 0.75
|
|
Ureteral Stent Symptom Questionnaire Score Up to 24 Hours After Stent Removal
Work
|
1.57 score on a scale
Standard Deviation 0.95
|
1.41 score on a scale
Standard Deviation 0.57
|
2.13 score on a scale
Standard Deviation 1.36
|
1.56 score on a scale
Standard Deviation 0.91
|
Adverse Events
Tamsulosin Plus Placebo 7 Day Treatment
Tamsulosin Plus Tolterodine ER 7 Day Treatment
Tamsulosin Plus Placebo 21 Day Treatment
Tamsulosin Plus Tolterodine ER 21 Day Treatment
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Shuang Li (Linda)
University of Wisconsin School of Medicine & Public Health
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place